amitriptyline has been researched along with Depression, Involutional in 110 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks." | 6.72 | Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. ( Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B, 2006) |
| " Tremor activity was assessed weekly, quantitatively by accelerometry and qualitatively with the Dosage Record and Treatment Emergent Symptom Scale." | 6.70 | Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. ( Bauer, M; Jobert, M; Müller-Oerlinghausen, B; Zaninelli, R, 2001) |
| "When depression was accompanied by character disorder, the response was generally poor." | 6.64 | A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. ( Davidson, J; Law-Yone, B; Linnoila, M; McLeod, M, 1978) |
| " We studied lipoprotein composition, insulin sensitivity (quantitative insulin sensitivity check index), and saliva cortisol in 78 depressed patients before and after 35 days of amitriptyline or paroxetin treatment." | 3.72 | Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. ( Deuschle, M; Gilles, M; Henn, FA; Heuser, I; Kopf, D; Lederbogen, F; Lehnert, H; Luley, CW; Ritter, S; Weber-Hamann, B; Westphal, S, 2004) |
| " The aim of research was to compare frequency of adverse events in cases of individualized and empiric dose regimens of amitriptyline in the treatment of major depressive episode." | 2.75 | Comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode. ( Borovcanin, M; Djukić-Dejanović, S; Janjić, V; Janković, S; Jovanović, M; Jovanović-Mihajlović, N; Mihajlović, G; Petrović, D; Radmanović, B, 2010) |
| " We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability." | 2.74 | Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. ( Miljkovic, B; Pokrajac, M; Prostran, M; Timotijevic, I; Todorovic, Z; Vezmar, S; Vucicevic, K, 2009) |
| "Seven of 10 patients responded to an increased dosage; all but 1 relapsed again on that dosage during follow-up." | 2.73 | Family intervention approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. ( Fabbri, S; Fava, GA; Rafanelli, C; Tomba, E, 2007) |
| "Forty-five inpatients with a chronic Major Depressive Disorder were randomized to 5 weeks of either Interpersonal Psychotherapy (IPT) modified for an inpatient setting (15 individual and 8 group sessions) plus pharmacotherapy or to medication plus Clinical Management (CM)." | 2.73 | Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients. ( Berger, M; Dykierek, P; Härter, M; Kech, S; Schneider, D; Schramm, E; van Calker, D; Zobel, I, 2008) |
| "Amitriptyline was the second tricyclic antidepressant to appear on the market for major depressive disorder under the brand name Elavil in 1961." | 2.72 | Classics in Chemical Neuroscience: Amitriptyline. ( Daniels, RN; McClure, EW, 2021) |
| "Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks." | 2.72 | Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. ( Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B, 2006) |
| "Treatment with amitriptyline tends to be associated with elevated platelet counts." | 2.71 | Platelet counts in depressed patients treated with amitriptyline or paroxetine. ( Deuschle, M; Hellweg, R; Heuser, I; Hörer, E; Lederbogen, F, 2003) |
| "Patients with major depression (ICD 10: F31-F33) and a HAMD-21 total score of 15-41 received At on a dosage schedule chosen by the doctor for at least 4 wks." | 2.71 | Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels. ( Franke, L; Müller-Oerlinghausen, B; Schewe, HJ; Uebelhack, R, 2003) |
| " Venlafaxine ER showed a more favorable safety profile than amitriptyline ER: adverse drug reactions were less frequent under venlafaxine ER than under amitriptyline ER." | 2.71 | Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. ( Dierkes, W; Huppertz-Helmhold, S; Sauer, H, 2003) |
| " The adverse effects were less frequent in the experimental group." | 2.71 | Comparison of efficacy and safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode. ( Jankovic, SM; Mihajlovic, GS; Milovanovic, DR, 2003) |
| " At the end of the double-blind phase, the blinded medication (lithium in 14 patients, placebo in 8 patients) was tapered off over a 1-week period, while the antidepressant was continued at the same dosage for another 4 weeks." | 2.70 | How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. ( Adli, M; Bauer, M; Berghöfer, A; Bschor, T; Kunz, D; Müller-Oerlinghausen, B; Ströhle, A, 2002) |
| " Tremor activity was assessed weekly, quantitatively by accelerometry and qualitatively with the Dosage Record and Treatment Emergent Symptom Scale." | 2.70 | Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. ( Bauer, M; Jobert, M; Müller-Oerlinghausen, B; Zaninelli, R, 2001) |
| "Amoxapine, a tricyclic dibenzoxazepine is an antidepressant which in the dosage range of 150-300 mg/day is notable for its rapid onset of action." | 2.65 | Systematic studies with amoxapine, a new antidepressant. ( Ban, TA; Fujimori, M; Petrie, WM; Ragheb, M; Wilson, WH, 1982) |
| "When depression was accompanied by character disorder, the response was generally poor." | 2.64 | A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. ( Davidson, J; Law-Yone, B; Linnoila, M; McLeod, M, 1978) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | 2.53 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| "Amitriptyline was significantly more effective than placebo in achieving acute response (18 RCTs, n = 1987, OR 2." | 2.48 | Amitriptyline versus placebo for major depressive disorder. ( Huhn, M; Leucht, C; Leucht, S, 2012) |
| "Treatment with ketamine, minocycline and amitriptyline were able to exert antidepressant effects in the forced swimming test." | 1.48 | Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events. ( Abelaira, HM; de Moura, AB; de Souza, TG; Fileti, ME; Garbossa, L; Goldim, MP; Maciel, AL; Mathias, K; Matos, D; Petronilho, F; Quevedo, J; Réus, GZ; Rosa, T; Strassi, AP; Tuon, T, 2018) |
| "Major depressive disorder is one of the most common diseases in western countries." | 1.43 | Regulation of Neuronal Stem Cell Proliferation in the Hippocampus by Endothelial Ceramide. ( Edwards, MJ; Grassmé, H; Gulbins, A; Gulbins, E; Hoehn, R; Kohnen, M; Kornhuber, J; Soddemann, M; Wilker, B, 2016) |
| " We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d." | 1.42 | Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015) |
| "Results demonstrated that underweight older patients were more likely to receive mirtazapine than any other antidepressant, prompting a systematic literature review to assess its potential role in appetite stimulation and weight gain." | 1.38 | Antidepressant use in underweight older adults. ( Avena-Woods, C; Hilas, O, 2012) |
| "The subjects were 313 patients with major depressive disorder and 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores between 14 and 25 who were treated for 6 months with either pharmacotherapy, short-term psychodynamic supportive psychotherapy or combined therapy." | 1.35 | Identifying patients at risk of complete nonresponse in the outpatient treatment of depression. ( Dekker, J; Peen, J; Schoevers, RA; van Aalst, G; Van, HL, 2008) |
| "A decision-tree model for the treatment of major depressive disorder was constructed using a Delphi panel." | 1.35 | Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. ( Burslem, K; Greenstreet, L; Knight, C; Lenox-Smith, A, 2009) |
| "Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm." | 1.35 | Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. ( Akechi, T; Akizuki, N; Ito, T; Nakano, T; Okamura, M; Shimizu, K; Uchitomi, Y, 2008) |
| "Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people." | 1.34 | Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007) |
| "Amitriptyline is a tricyclic antidepressant that is historically indicated and used to manage depression." | 1.33 | Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. ( Dukes, E; Gore, M; Leslie, DL; Rowbotham, D; Tai, KS, 2006) |
| "Eight cases of glossodynia arising in the context of an endogenous depression are reported and the case histories of four of them are presented." | 1.27 | [Vital disorders of the mouth (glossodynia) in depressive involutional psychoses]. ( Maier, C, 1986) |
| "For depressive neurosis and involutional melancholia best therapeutic responses were yielded at a dosage of 50 mg, while in the treatment of manic-depressive illness, comparable results occurred at a 150 mg dosage." | 1.26 | Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders. ( Corona, GL; Cucchi, ML; Fenoglio, L; Frattini, P; Pinelli, P; Santagostino, G; Zerbi, F, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (31.82) | 18.7374 |
| 1990's | 3 (2.73) | 18.2507 |
| 2000's | 42 (38.18) | 29.6817 |
| 2010's | 23 (20.91) | 24.3611 |
| 2020's | 7 (6.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kishi, T | 1 |
| Ikuta, T | 1 |
| Sakuma, K | 1 |
| Okuya, M | 1 |
| Hatano, M | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Joas, E | 1 |
| Jonsson, L | 1 |
| Viktorin, A | 1 |
| Smedler, E | 1 |
| Pålsson, E | 1 |
| Goodwin, GM | 1 |
| Landén, M | 1 |
| Rao, Y | 1 |
| Yang, R | 1 |
| Zhao, J | 1 |
| Cao, Q | 1 |
| Holper, L | 1 |
| Kwon, Y | 1 |
| Bang, Y | 1 |
| Moon, SH | 1 |
| Kim, A | 1 |
| Choi, HJ | 1 |
| McClure, EW | 1 |
| Daniels, RN | 1 |
| Kazemi, A | 1 |
| Shulman, K | 1 |
| Russo, M | 1 |
| Tiihonen, J | 1 |
| Tanskanen, A | 1 |
| Hoti, F | 1 |
| Vattulainen, P | 1 |
| Taipale, H | 1 |
| Mehtälä, J | 1 |
| Lähteenvuo, M | 1 |
| Maciel, AL | 1 |
| Abelaira, HM | 1 |
| de Moura, AB | 1 |
| de Souza, TG | 1 |
| Rosa, T | 1 |
| Matos, D | 1 |
| Tuon, T | 1 |
| Garbossa, L | 1 |
| Strassi, AP | 1 |
| Fileti, ME | 1 |
| Goldim, MP | 1 |
| Mathias, K | 1 |
| Petronilho, F | 1 |
| Quevedo, J | 1 |
| Réus, GZ | 1 |
| Kessing, LV | 1 |
| Bukh, JD | 1 |
| Nakimuli-Mpungu, E | 1 |
| Odokonyero, R | 1 |
| Laker, J | 1 |
| Alderman, S | 1 |
| Berm, EJJ | 1 |
| Paardekooper, J | 1 |
| Brummel-Mulder, E | 1 |
| Hak, E | 1 |
| Wilffert, B | 1 |
| Maring, JG | 1 |
| Flores-Serrano, AG | 1 |
| Zaldívar-Rae, J | 1 |
| Salgado, H | 1 |
| Pineda, JC | 1 |
| Hisaoka-Nakashima, K | 1 |
| Miyano, K | 1 |
| Matsumoto, C | 1 |
| Kajitani, N | 1 |
| Abe, H | 1 |
| Okada-Tsuchioka, M | 1 |
| Yokoyama, A | 1 |
| Uezono, Y | 1 |
| Morioka, N | 1 |
| Nakata, Y | 1 |
| Takebayashi, M | 1 |
| Hayasaka, Y | 1 |
| Purgato, M | 1 |
| Magni, LR | 1 |
| Ogawa, Y | 1 |
| Takeshima, N | 1 |
| Cipriani, A | 2 |
| Barbui, C | 1 |
| Leucht, S | 3 |
| Furukawa, TA | 2 |
| Arco, L | 1 |
| Miskovic, M | 1 |
| Zhou, X | 1 |
| Del Giovane, C | 1 |
| Hetrick, SE | 1 |
| Qin, B | 1 |
| Whittington, C | 1 |
| Coghill, D | 1 |
| Zhang, Y | 1 |
| Hazell, P | 1 |
| Cuijpers, P | 1 |
| Pu, J | 1 |
| Cohen, D | 1 |
| Ravindran, AV | 1 |
| Liu, Y | 1 |
| Michael, KD | 1 |
| Yang, L | 1 |
| Liu, L | 1 |
| Xie, P | 1 |
| Gulbins, A | 1 |
| Grassmé, H | 1 |
| Hoehn, R | 1 |
| Wilker, B | 1 |
| Soddemann, M | 1 |
| Kohnen, M | 1 |
| Edwards, MJ | 1 |
| Kornhuber, J | 1 |
| Gulbins, E | 1 |
| Van, HL | 1 |
| Dekker, J | 1 |
| Peen, J | 1 |
| van Aalst, G | 1 |
| Schoevers, RA | 1 |
| van Calker, D | 3 |
| Zobel, I | 3 |
| Dykierek, P | 3 |
| Deimel, CM | 1 |
| Kech, S | 3 |
| Lieb, K | 3 |
| Berger, M | 3 |
| Schramm, E | 3 |
| Lenox-Smith, A | 1 |
| Greenstreet, L | 1 |
| Burslem, K | 1 |
| Knight, C | 1 |
| Vezmar, S | 1 |
| Miljkovic, B | 1 |
| Vucicevic, K | 1 |
| Timotijevic, I | 1 |
| Prostran, M | 1 |
| Todorovic, Z | 1 |
| Pokrajac, M | 1 |
| Langguth, B | 1 |
| Landgrebe, M | 1 |
| Wittmann, M | 1 |
| Kleinjung, T | 1 |
| Hajak, G | 1 |
| Mihajlović, G | 1 |
| Djukić-Dejanović, S | 1 |
| Jovanović-Mihajlović, N | 1 |
| Janković, S | 1 |
| Janjić, V | 1 |
| Jovanović, M | 1 |
| Petrović, D | 1 |
| Borovcanin, M | 1 |
| Radmanović, B | 1 |
| Paslakis, G | 1 |
| Kopf, D | 2 |
| Westphal, S | 2 |
| Gilles, M | 3 |
| Lederbogen, F | 5 |
| Hamann, B | 3 |
| Heuser, I | 9 |
| Deuschle, M | 9 |
| Andjelkovic, M | 1 |
| Jovanovic, DB | 1 |
| Zdravkovic, N | 1 |
| Jankovic, SM | 2 |
| Miljevic, CD | 1 |
| Kecojevic-Miljevic, S | 1 |
| Crnobaric, C | 1 |
| Lecic-Tosevski, D | 1 |
| Johnston, BC | 1 |
| Thorlund, K | 1 |
| da Costa, BR | 1 |
| Guyatt, GH | 1 |
| Thase, ME | 1 |
| Peñas-Lledó, EM | 1 |
| Trejo, HD | 1 |
| Dorado, P | 1 |
| Ortega, A | 1 |
| Jung, H | 1 |
| Alonso, E | 1 |
| Naranjo, ME | 1 |
| López-López, M | 1 |
| Llerena, A | 1 |
| Sommer, C | 1 |
| Häuser, W | 1 |
| Alten, R | 1 |
| Petzke, F | 1 |
| Späth, M | 1 |
| Tölle, T | 1 |
| Uçeyler, N | 1 |
| Winkelmann, A | 1 |
| Winter, E | 1 |
| Bär, KJ | 1 |
| Avena-Woods, C | 1 |
| Hilas, O | 1 |
| Leucht, C | 1 |
| Huhn, M | 1 |
| Ohishi, M | 1 |
| Kamijima, K | 1 |
| Bschor, T | 1 |
| Berghöfer, A | 1 |
| Ströhle, A | 1 |
| Kunz, D | 1 |
| Adli, M | 1 |
| Müller-Oerlinghausen, B | 3 |
| Bauer, M | 2 |
| Kostiukova, EG | 1 |
| Granenov, GM | 1 |
| Andreĭchik, LA | 1 |
| Serditov, OV | 1 |
| Mosolov, SN | 1 |
| Meichel, C | 1 |
| Krumm, B | 1 |
| Kniest, A | 3 |
| Colla, M | 2 |
| Hörer, E | 1 |
| Hellweg, R | 1 |
| Niederhofer, H | 1 |
| Franke, L | 1 |
| Schewe, HJ | 1 |
| Uebelhack, R | 1 |
| DECLICH, M | 1 |
| MOROSINI, C | 1 |
| BARCIASALORIO, D | 1 |
| ROPERT, R | 1 |
| KAMMERER, T | 1 |
| GEISSMANN, P | 1 |
| BUCHHEIT, F | 1 |
| WARTEL, R | 1 |
| THONIER, M | 1 |
| PETIT, P | 1 |
| ROURE, J | 1 |
| MANS, J | 1 |
| SENES, M | 1 |
| POELDINGER, W | 1 |
| HOENIG, J | 1 |
| VISRAM, S | 1 |
| Sauer, H | 1 |
| Huppertz-Helmhold, S | 1 |
| Dierkes, W | 1 |
| Mihajlovic, GS | 1 |
| Milovanovic, DR | 1 |
| Gandjour, A | 1 |
| Lauterbach, KW | 1 |
| Pollard, AJ | 1 |
| Prendergast, M | 1 |
| Luley, CW | 1 |
| Ritter, S | 1 |
| Weber-Hamann, B | 2 |
| Lehnert, H | 1 |
| Henn, FA | 1 |
| Niemann, H | 1 |
| Erb-Bies, M | 1 |
| Colla, N | 1 |
| Rumi, DO | 1 |
| Gattaz, WF | 1 |
| Rigonatti, SP | 1 |
| Rosa, MA | 1 |
| Fregni, F | 1 |
| Rosa, MO | 1 |
| Mansur, C | 1 |
| Myczkowski, ML | 1 |
| Moreno, RA | 1 |
| Marcolin, MA | 1 |
| Rota, E | 1 |
| Broda, R | 1 |
| Cangemi, L | 1 |
| Migliaretti, G | 1 |
| Paccotti, P | 1 |
| Rosso, C | 1 |
| Torre, E | 1 |
| Zeppegno, P | 1 |
| Portaleone, P | 1 |
| Schürks, M | 1 |
| Overlack, M | 1 |
| Bonnet, U | 1 |
| Sander, P | 1 |
| Herpfer, I | 1 |
| Fiebich, BL | 1 |
| Laske, C | 1 |
| Stransky, E | 1 |
| Eschweiler, GW | 1 |
| Klein, R | 1 |
| Wittorf, A | 1 |
| Leyhe, T | 1 |
| Richartz, E | 1 |
| Köhler, N | 1 |
| Bartels, M | 1 |
| Buchkremer, G | 1 |
| Schott, K | 1 |
| Kronenberg, G | 1 |
| Meichel, K | 1 |
| Hagen, T | 1 |
| Bohrer, M | 1 |
| Rachid, F | 1 |
| Golaz, J | 1 |
| Bondolfi, G | 1 |
| Bertschy, G | 1 |
| Gore, M | 1 |
| Dukes, E | 1 |
| Rowbotham, D | 1 |
| Tai, KS | 1 |
| Leslie, DL | 1 |
| Rosenberg, C | 1 |
| Lauritzen, L | 1 |
| Brix, J | 1 |
| Jørgensen, JB | 1 |
| Kofod, P | 1 |
| Bayer, LB | 1 |
| Gareri, P | 1 |
| De Fazio, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Okamura, M | 1 |
| Akizuki, N | 1 |
| Nakano, T | 1 |
| Shimizu, K | 1 |
| Ito, T | 1 |
| Akechi, T | 1 |
| Uchitomi, Y | 1 |
| Leonhart, R | 1 |
| Gourley, SL | 1 |
| Wu, FJ | 1 |
| Kiraly, DD | 1 |
| Ploski, JE | 1 |
| Kedves, AT | 1 |
| Duman, RS | 1 |
| Taylor, JR | 1 |
| Fabbri, S | 1 |
| Fava, GA | 1 |
| Rafanelli, C | 1 |
| Tomba, E | 1 |
| Schneider, D | 1 |
| Härter, M | 1 |
| Bijl, MJ | 1 |
| Visser, LE | 1 |
| Hofman, A | 1 |
| Vulto, AG | 1 |
| van Gelder, T | 1 |
| Stricker, BH | 1 |
| van Schaik, RH | 1 |
| Bourgeois, M | 1 |
| Ulrich, G | 1 |
| Renfordt, E | 1 |
| Zeller, G | 1 |
| Frick, K | 1 |
| Ban, TA | 2 |
| Fujimori, M | 1 |
| Petrie, WM | 2 |
| Ragheb, M | 1 |
| Wilson, WH | 2 |
| Jamieson, RC | 1 |
| Guy, W | 1 |
| Corona, GL | 1 |
| Pinelli, P | 1 |
| Zerbi, F | 1 |
| Fenoglio, L | 1 |
| Santagostino, G | 1 |
| Frattini, P | 1 |
| Cucchi, ML | 1 |
| Steiger, A | 1 |
| Holsboer, F | 1 |
| Birmaher, B | 1 |
| Waterman, GS | 1 |
| Ryan, ND | 1 |
| Perel, J | 1 |
| McNabb, J | 1 |
| Balach, L | 1 |
| Beaudry, MB | 1 |
| Nasr, FN | 1 |
| Karambelkar, J | 1 |
| Elterich, G | 1 |
| Quintana, H | 1 |
| Williamson, DE | 1 |
| Rao, U | 1 |
| Lehofer, M | 1 |
| Moser, M | 1 |
| Hoehn-Saric, R | 1 |
| McLeod, D | 1 |
| Hildebrandt, G | 1 |
| Egner, S | 1 |
| Steinbrenner, B | 1 |
| Liebmann, P | 1 |
| Zapotoczky, HG | 1 |
| Gentil, V | 1 |
| Kerr-Correa, F | 1 |
| Moreno, R | 1 |
| D'Arrigo Busnello, E | 1 |
| De Campos, JA | 1 |
| Juruena, MF | 1 |
| Lafer, B | 1 |
| Moreno, DH | 1 |
| De Cassia Rodrigues, RL | 1 |
| Tiosso, A | 1 |
| Benedictis, E | 1 |
| Möller, HJ | 1 |
| Glaser, K | 1 |
| Leverkus, F | 1 |
| Göbel, C | 1 |
| Sattler, HD | 1 |
| Richter, P | 1 |
| Fritzsche, M | 1 |
| von Turner, A | 1 |
| Barnett, W | 1 |
| Amann, B | 1 |
| Grunze, H | 1 |
| Hoffmann, J | 1 |
| Schäfer, M | 1 |
| Kuss, HJ | 1 |
| Zaninelli, R | 1 |
| Jobert, M | 1 |
| Wiegand, MH | 1 |
| Lauer, CJ | 1 |
| Schreiber, W | 1 |
| Bech, P | 1 |
| Henning, O | 1 |
| Niedermaier, N | 1 |
| Watanabe, S | 1 |
| Yokoyama, S | 1 |
| Kubo, S | 1 |
| Iwai, H | 1 |
| Kuyama, C | 1 |
| Delaunay, J | 1 |
| Meynard, J | 1 |
| Strian, F | 1 |
| Albert, W | 1 |
| Klicpera, C | 1 |
| Rydzyński, Z | 1 |
| Gruszczyński, W | 1 |
| Davidson, J | 1 |
| McLeod, M | 1 |
| Law-Yone, B | 1 |
| Linnoila, M | 1 |
| Scotto, JC | 1 |
| Dufour, H | 1 |
| Huber, JP | 1 |
| Crespin, J | 1 |
| Pin, M | 1 |
| Joseph, A | 1 |
| Sutter, JM | 1 |
| Litvinova, NM | 1 |
| Kabachenko, EN | 1 |
| Maier, C | 1 |
| Savitsky, E | 1 |
| Radmayr, E | 1 |
| Gol'dovskaia, IL | 2 |
| Bente, D | 1 |
| Feder, J | 1 |
| Belmchen, H | 1 |
| Hippius, H | 1 |
| Rosenberg, L | 1 |
| Bercel, NA | 1 |
| Fracchia, J | 1 |
| Sheppard, C | 1 |
| Merlis, S | 1 |
| Rajotte, P | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Doucet, P | 1 |
| Rajotte, E | 1 |
| Sedivec, V | 1 |
| Valenová, Z | 1 |
| Paceltová, L | 1 |
| Náhunek, K | 1 |
| Svestka, J | 1 |
| Rodová, A | 1 |
| Maiss, HJ | 1 |
| Post, F | 1 |
| Hader, M | 1 |
| Madonick, JJ | 1 |
| Rosenblatt, S | 1 |
| Chanley, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-14 | Withdrawn (stopped due to Unable to obtain investigational product) | ||
| Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients[NCT01049347] | Phase 3 | 127 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Neuroimaging Biomarker-Guided Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Episode in Adolescents and Young Adults With Mood Disorders: A Randomized, Double-Blind, Controlled Study[NCT05465928] | 120 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Investigation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Therapy in Patients With Post-stroke Depression (PSD)[NCT03761303] | 0 participants (Actual) | Interventional | 2018-05-01 | Withdrawn (stopped due to No eligible patients could be recruited.) | |||
| Randomised Control Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder[NCT01047124] | 219 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | |||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
7 reviews available for amitriptyline and Depression, Involutional
| Article | Year |
|---|---|
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Dul | 2022 |
Classics in Chemical Neuroscience: Amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Selective Serot | 2021 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].
Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Antidepressive Agents; Anxiety Disorders; Combined Mo | 2012 |
Amitriptyline versus placebo for major depressive disorder.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Placebo | 2012 |
Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.
Topics: Adult; Affect; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Res | 2001 |
38 trials available for amitriptyline and Depression, Involutional
| Article | Year |
|---|---|
Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Combined Modality Therapy; Depressive | 2009 |
Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; De | 2009 |
Comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode.
Topics: Adverse Drug Reaction Reporting Systems; Amitriptyline; Antidepressive Agents, Tricyclic; Bayes Theo | 2010 |
Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; | 2011 |
Gallbladder emptying in patients with major depression: a case series.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Case-Control Studies; Depressive Diso | 2011 |
How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major | 2002 |
[Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital].
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major | 2003 |
Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations.
Topics: Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Hydrocortisone; Hy | 2003 |
Platelet counts in depressed patients treated with amitriptyline or paroxetine.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Male; M | 2003 |
Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Data Interpretation | 2003 |
Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Cyclohexanols; Delayed-Action Preparations; | 2003 |
Comparison of efficacy and safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode.
Topics: Adult; Aged; Aging; Amitriptyline; Antidepressive Agents; Bayes Theorem; Depressive Disorder, Major; | 2003 |
Impaired declarative memory in depressed patients is slow to recover: clinical experience.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statisti | 2004 |
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distributio | 2005 |
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distributio | 2005 |
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distributio | 2005 |
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distributio | 2005 |
Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Diso | 2005 |
Hippocampal volume reduction and HPA-system activity in major depression.
Topics: Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents; Cephalometry; Depressive Disorder, M | 2007 |
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Di | 2006 |
Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Age | 2007 |
An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cohort Studies; Combi | 2007 |
Family intervention approach to loss of clinical effect during long-term antidepressant treatment: a pilot study.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modality The | 2007 |
Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Chronic Disease; Combined Modality Th | 2008 |
Systematic studies with amoxapine, a new antidepressant.
Topics: Adult; Amitriptyline; Amoxapine; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; De | 1982 |
Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression.
Topics: Adolescent; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Respon | 1998 |
Influence of age on the parasympatholytic property of tricyclic antidepressants.
Topics: Adult; Aging; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; H | 1999 |
Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.
Topics: Adolescent; Adult; Ambulatory Care; Amitriptyline; Antidepressive Agents, Second-Generation; Antidep | 2000 |
Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, | 2000 |
Neurophysiologic tests during antidepressive treatment - an exploratory study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Depressive D | 2000 |
Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antimanic Agents; Depressive Disorder, Major; Dou | 2001 |
Amitriptyline and paroxetine: effects upon peripheral nervous system (PNS).
Topics: Adult; Aged; Amitriptyline; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Motor Neu | 2002 |
A double-blind controlled study of clinical efficacy of maprotiline and amitriptyline in depression.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Amitriptyline; Anthracenes; Bipolar Disorde | 1978 |
[Clinical and comparative trial of dosulepin and amitriptyline].
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amitriptyline; Anxiety Disorders; Clinical Trials as | 1978 |
A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression.
Topics: Adjustment Disorders; Adult; Affective Disorders, Psychotic; Amitriptyline; Depression; Depressive D | 1978 |
[Amitriptyline in psychiatric therapeutics. Apropos of 8 years of its use in hospital practice].
Topics: Adjustment Disorders; Adult; Aged; Amitriptyline; Clinical Trials as Topic; Depression; Depressive D | 1976 |
Psychopharmacology in the aged. Discussion.
Topics: Age Factors; Aged; Amitriptyline; Antipsychotic Agents; Bipolar Disorder; Brain Damage, Chronic; Dep | 1974 |
[Double-blind study on 3 antidepressive agents. 2. Clinical comparison of noxiptiline, nor-noxiptiline, and amitryptiline using the AMP system].
Topics: Adjustment Disorders; Adolescent; Adult; Affective Symptoms; Aged; Amitriptyline; Analysis of Varian | 1973 |
Clinical trial of protriptyline (Vivactil).
Topics: Amitriptyline; Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depression; Depres | 1967 |
Combination medications in psychiatric treatment: patterns in a group of elderly hospital patients.
Topics: Age Factors; Aged; Amitriptyline; Antidepressive Agents; Antihypertensive Agents; Antisocial Persona | 1971 |
A double-blind comparative study of opipramol and amitriptyline in neurotic and endogenous depressions.
Topics: Amitriptyline; Bipolar Disorder; Classification; Clinical Trials as Topic; Depression; Depressive Di | 1966 |
65 other studies available for amitriptyline and Depression, Involutional
| Article | Year |
|---|---|
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.
Topics: Amitriptyline; Antidepressive Agents; Bipolar Disorder; Clomipramine; Cytochrome P-450 CYP2C19; Cyto | 2023 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disor | 2020 |
Amitriptyline interferes with autophagy-mediated clearance of protein aggregates via inhibiting autophagosome maturation in neuronal cells.
Topics: Amitriptyline; Animals; Autophagosomes; Autophagy; Depressive Disorder, Major; Lysosomes; Neurodegen | 2020 |
Amitriptyline-Induced Multifocal Oral Mucosal Dyspigmentation-Bridging Pharmacopsychodermatology in Skin of Color.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Asian People; Biopsy; Communication Barriers | 2021 |
Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antipsychotic Agents; Clozapine; Cohort Studies; | 2017 |
Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antioxidants; Brain; Chronic Disease; Depressive Diso | 2018 |
[Amitriptyline versus placebo for major depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Nortriptyline; | 2013 |
Major depression in postconflict northern Uganda: a case report.
Topics: Amitriptyline; Anti-Retroviral Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; | 2014 |
A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Biotransformation; Calibration; Chromatography, Liq | 2015 |
Immobility time during the forced swimming test predicts sensitivity to amitriptyline, whereas traveled distance in the circular corridor indicates resistance to treatment in female Wistar rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depressive Disorder, Maj | 2015 |
Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Astrocytes; Biosensing Techniques; Cell Li | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose | 2015 |
A case study in treating chronic comorbid obsessive-compulsive disorder and depression with behavioral activation and pharmacotherapy.
Topics: Amitriptyline; Antidepressive Agents; Behavior Therapy; Chronic Disease; Clomipramine; Depressive Di | 2015 |
Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Age | 2015 |
Regulation of Neuronal Stem Cell Proliferation in the Hippocampus by Endothelial Ceramide.
Topics: 11-Hydroxycorticosteroids; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Cell Line; Cell | 2016 |
Identifying patients at risk of complete nonresponse in the outpatient treatment of depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Combined Modality Th | 2008 |
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Bene | 2009 |
Persistent tinnitus induced by tricyclic antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Dis | 2010 |
A rare case of male hysteria - hemiparesis successfully treated with amitriptyline.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2011 |
New methods can extend the use of minimal important difference units in meta-analyses of continuous outcome measures.
Topics: Amitriptyline; Antidepressive Agents; Confidence Intervals; Data Interpretation, Statistical; Depres | 2012 |
Social skills training for depression and comparative efficacy research: a 30-year retrospective.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Behavior Therapy; Depressive Disorder, Major; Femal | 2012 |
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
Topics: Amitriptyline; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Resp | 2013 |
Antidepressant use in underweight older adults.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weigh | 2012 |
A comparison of characteristics of depressed patients and efficacy of sertraline and amitriptyline between Japan and the West.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Europe; Female; Human | 2002 |
[Therapy resistant major depression: improvement of symptomatology after combining antidepressants with Tianeptine (Stablon)].
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Drug Resistance | 2003 |
[ON THE USE OF AMITRIPTYLINE IN THE THERAPY OF ENDOGENOUS DEPRESSIVE PSYCHOSES].
Topics: Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Major; Mental | 1963 |
[STUDY OF CEREBRAL HEMODYNAMICS IN THE DEPRESSIVE STATES].
Topics: Amitriptyline; Bipolar Disorder; Cerebrovascular Circulation; Depression; Depressive Disorder; Depre | 1963 |
[OUR CLINICAL EXPERIENCE WITH AMITRIPTYLINE].
Topics: Adolescent; Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, M | 1963 |
[CLINICAL, BIOLOGICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF THE ACTION OF MK 230 IN DEPRESSIVE SYNDROMES].
Topics: Amitriptyline; Depression; Depressive Disorder; Depressive Disorder, Major; Humans; Psychotic Disord | 1963 |
[VALUE OF AMINOTRIPTYLINE IN THE TREATMENT OF DEPRESSIVE STATES].
Topics: Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Major; Humans | 1964 |
[AMITRIPTYLINE OR LAROXYL IN DEPRESSIVE SYNDROMES].
Topics: Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Major; Epilep | 1964 |
[LAROXYL (AMITRIPTYLINE), A THYMOLEPTIC WITH A NEUROLEPTIC EFFICACY COMPONENT].
Topics: Amitriptyline; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Chlordiazepoxide; Chlo | 1963 |
AMITRIPTYLINE VERSUS IMIPRAMINE IN DEPRESSIVE PSYCHOSES.
Topics: Amitriptyline; Biomedical Research; Bipolar Disorder; Depression; Depressive Disorder; Depressive Di | 1964 |
[At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example].
Topics: Amitriptyline; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; | 2004 |
Depressive pseudodementia in a child with autism.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Autistic Disorder; Child; Dementia; Depressive Diso | 2004 |
Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Blood Gl | 2004 |
Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Amitriptyline; Circadian Rhythm; Depressive Disorder, Majo | 2005 |
Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.
Topics: Alcoholism; Amitriptyline; Depressive Disorder, Major; Ethanol; Humans; Male; Middle Aged; Morphine; | 2005 |
Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2007 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Analgesics, | 2006 |
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi | 2007 |
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
Topics: Adult; Aged; Algorithms; Alprazolam; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzod | 2008 |
Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression.
Topics: Amitriptyline; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Chronic Disease; | 2008 |
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Body Weight; Cohort Studies; Cytochrome P-450 | 2008 |
[Study of an antidepressive agent in psychiatry: Mutabon F].
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amitriptyline; Anxiety Disorders; Bipolar Disorder; D | 1967 |
Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question.
Topics: Amitriptyline; Antidepressive Agents; Carbazoles; Depressive Disorder, Major; Double-Blind Method; E | 1984 |
Viloxazine in the treatment of endogenous depression. A standard (amitriptyline) controlled clinical study.
Topics: Adolescent; Adult; Amitriptyline; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Major; | 1982 |
Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders.
Topics: Adjustment Disorders; Adult; Aged; Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder, | 1980 |
Nocturnal secretion of prolactin and cortisol and the sleep EEG in patients with major endogenous depression during an acute episode and after full remission.
Topics: Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Cerebral Cortex; Circadia | 1997 |
[Non-fatal effect of highly toxic amitriptyline level after suicide attempt. A case report].
Topics: Adult; Amitriptyline; Critical Care; Depressive Disorder, Major; Dose-Response Relationship, Drug; D | 2001 |
Patterns of response to repeated total sleep deprivations in depression.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Male; M | 2001 |
Antidepressive treatment and mood swing patterns in endogenous depression.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Clomipra | 1979 |
Viloxazine in the treatment of depressive states.
Topics: Adjustment Disorders; Amitriptyline; Depression; Depressive Disorder, Major; Double-Blind Method; Hu | 1979 |
[Prediction of the effect of antidepressants in patients with endogenous depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Fe | 1986 |
[Vital disorders of the mouth (glossodynia) in depressive involutional psychoses].
Topics: Aged; Amitriptyline; Chlorpromazine; Depressive Disorder, Major; Drug Therapy, Combination; Female; | 1986 |
[Ambulatory management of depressions using doxepin].
Topics: Adjustment Disorders; Ambulatory Care; Amitriptyline; Bipolar Disorder; Chemical Phenomena; Chemistr | 1969 |
[The possibilities and limitations of psychotropic drug therapy for patients with glaucoma].
Topics: Aged; Alcoholism; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Chronic Disease; Dementia; | 1974 |
[Ophthalmologic study of patients receiving psychotropic drugs].
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Cataract; Cerebrova | 1970 |
Persistent extrapyramidal oral dyskinesias following treatment with thymoleptics.
Topics: Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Facial Muscles; Female; Huma | 1970 |
Clinical test of protriptyline in endogenous and involutional depressions.
Topics: Adolescent; Adult; Aged; Amitriptyline; Depression; Depressive Disorder, Major; Female; Hallucinatio | 1970 |
[Therapy of psycho-autonomic and dysphoric syndromes in the general practice].
Topics: Adjustment Disorders; Adult; Amitriptyline; Anxiety; Bipolar Disorder; Chlordiazepoxide; Climacteric | 1968 |
Management of senile psychiatric disorders.
Topics: Adjustment Disorders; Affective Symptoms; Aged; Alcoholism; Amitriptyline; Dementia; Depressive Diso | 1968 |
Experiences with amitriptyline in elderly patients.
Topics: Aged; Amitriptyline; Brain Damage, Chronic; Dementia; Depression; Depressive Disorder, Major; Female | 1966 |
The metabolism of norepinephrine in depressions. Differences and effects of therapies.
Topics: Adult; Aged; Amitriptyline; Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Depression; Depressi | 1966 |